SCHEMBL6561048

SCHEMBL6561048

COc1nc2ccccc2nc1NC(=O)N1CCN(c2cc(N)cc(N)c2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.43
KMT2A Q03164 4/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
MAPK1 P28482 2/20 0.43
GAA P10253 1/20 0.43
RBP4 P02753 1/20 0.43
LMNA P02545 3/20 0.42
ALDH1A1 P00352 2/20 0.42
TP53 P04637 2/20 0.42
KDM4E B2RXH2 2/20 0.41
GLA P06280 1/20 0.41
USP2 O75604 2/20 0.41
POLB P06746 2/20 0.41
MEN1 O00255 2/20 0.41
HCRTR1 O43613 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6559618 0.90 MAPT (0.44) MAPTKMT2AL3MBTL1MAPK1GAA
SCHEMBL6559685 0.89 MAPT (0.50) MAPTKMT2AL3MBTL1MAPK1GAA
SCHEMBL6560691 0.88 RBP4 (0.51) MAPTKMT2AL3MBTL1MAPK1GAA
SCHEMBL3442752 0.88 ALDH1A1 (0.53) MAPTKMT2AL3MBTL1MAPK1GAA
SCHEMBL6560742 0.87 MAPT (0.48) MAPTKMT2AL3MBTL1MAPK1GAA
SCHEMBL6559653 0.86 MAPT (0.39) MAPTKMT2AL3MBTL1MAPK1GAA
SCHEMBL7795033 0.85 MAPT (0.40) MAPTKMT2AL3MBTL1MAPK1GAA
SCHEMBL6562785 0.84 KMT2A (0.49) MAPTKMT2AL3MBTL1MAPK1GAA
SCHEMBL6560277 0.83 KMT2A (0.48) MAPTKMT2AL3MBTL1MAPK1GAA
SCHEMBL6561550 0.83 MAPT (0.53) MAPTKMT2AL3MBTL1MAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1075469-B1 PIPERAZINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF SAMJIN PHARM CO LTD (KR) 2004-05-26 EP disclosed
US-6683184-B2 ANTITUMOR AGENTS SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2004-01-27 US disclosed
US-20030092910-A1 Piperazine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2003-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092910-A1 Piperazine derivatives and process for the preparation thereof CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS MAPT 4877/4885KMT2A 2664/4885L3MBTL1 2717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.